Navigation Links
Newly Released Canadian Data Links Vaccines with Pervasive,Developmental Disorder

National Autism Association calls 2006 Pediatrics study fatally flawed

CHICAGO, March 07, 2007 /PRNewswire-USNewswire/ -- New findings presented yesterday at a National Autism Association meeting bolster claims that vaccines may play a role in the development of autism spectrum disorders. David Ayoub, MD presented data suggesting a correlation between mercury- containing vaccines and rates of pervasive developmental disorder (PDD), a form of autism, in Montreal. The peak rate of one in 87 children diagnosed with PDD occurred following the period of greatest exposure to the mercury- based vaccine preservative thimerosal. A flattening of the rates studied is now emerging as mercury-containing vaccines have been gradually eliminated from the routine schedule.

This new data points out flaws in a 2006 study published in the journal Pediatrics by Eric Fombonne, MD, et al, which found PDD rates continued to increase even when rates of MMR vaccination and use of mercury-containing vaccines decreased. The study population consisted of a single Montreal school board that was an Autism Center of Excellence, suggesting an over- ascertainment of regional diagnoses. Dr. Ayoub and co-authors Monica Ruscitti, BA, and F. Edward Yazbak, MD broadened the data to include all five Montreal school boards.

The earlier study also reported PDD rates in children from Montreal, but MMR coverage data was taken from Quebec City located 265km from Montreal. The researchers confirmed MMR coverage rates actually increased in Montreal along with PDD, noting a sharper rise in rates after the number of required MMR shots doubled.

The Pediatrics paper claimed there was no exposure to mercury from vaccines post-1996 although several mercury-containing vaccines were administered well beyond 1996. "It's irresponsible that such flawed data was published in a medical journal. This new information confirms a relationship between va ccines and autism that can't be explained by better diagnosing or changing diagnostic criteria," said Karen McDonough, NAA -- Chicago president.

Drs. Ayoub and Yazbak detailed the Fombonne study flaws in letters to Pediatrics which the journal declined to publish. Editor Jerold F. Lucey, MD stated in a reply, "I believe the evidence of no link between MMR and Autism is sufficient. It's not worth publishing more on this subject."

"This dismissal of legitimate concerns regarding data affecting those suffering with autism is a disgrace," commented Ms. McDonough.

     For more information:

     Contacts:  Wendy Fournier 401-632-7523

                Rita Shreffler 417-818-9030

CONTACT: Wendy Fournier, +1-401-632-7523, or Rita Shreffler,+1-417-818-9030, both of National Autism Association

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
6. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
7. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
8. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
9. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
10. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):